medigraphic.com

2020, Number 2

<< Back Next >>

Rev Clin Esc Med 2020; 10 (2)

Uso de inhibidores de mTOR en el Trasplante Renal

Arley VDA, Morales RJA, López CLA

Language: Spanish
References: 36
Page: 9-14
PDF size: 126.93 Kb.


ABSTRACT

In patients with advanced chronic kidney disease, kidney transplantation is the main therapeutic measure to be implemented; however, the immune system must be modulated to prevent the risk of renal graft loss. The immunosuppressive treatment should be individualized according to the immunological risk of each patient; mTOR are an alternative that should be considered in patients who will undergo a kidney transplant, there are different protocols for use, these modalities of drug initiation can be from Novo conversion, early conversion and late conversion; each brings advantages and disadvantages to the transplanted patient. The drug is not except for side effects to be considered among the most prominent dyslipidemia, delay in wound healing, pneumonitis and the risk of acute humoral rejection.


REFERENCES

  1. Eknoyan, G. et al. Kdigo 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements (2013). Vol 3 | issue 1 | january (1) 2013.

  2. Webster, A. et al. Chronic kidney disease. Lancet 2017; 389: 1238–52. http://dx.doi.org/10.1016/ s0140- 6736(16)32064-5

  3. Romagnani, P. et al. Chronic kidney disease. Nature reviews | disease primers volume 3 | article number 17088 | 3. Doi:10.1038/nrdp.2017.88

  4. Hill Nr, Fatoba St, Oke Jl, Hirst Ja, O’callaghan Ca, Lasserson Ds, et al. (2016) global prevalence of chronic kidney disease – a systematic review and meta- analysis. Plos one 11(7): e0158765. Doi:10.1371/ journal.pone.0158765

  5. Yaghoubifard S, Goudarzi R, Etminan A, Baneshi Mr, Barouni M, Jafari Sirizi M. Cost-effectiveness analysis of dialysis and kidney transplant in patients with renal impairment using disability adjusted life years in iran. Med j islam repub iran 2016 (28 june). Vol. 30:390.

  6. Bongiovanni I, et al. Evaluation medico-economique des strategies de prise en charge de l’insuffisance renale chronique terminale en france. Nephrol ther (2016), http://dx.doi.org/10.1016/j. nephro.2015.10.004.

  7. Villa, G. et al. Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in spain. Bmc health services research 2012, 12:257. http:// www.biomedcentral.com/1472-6963/12/257.

  8. Rosselli, D. Et al. Cost-effectiveness of kidney transplantation compared with chronic dialysis in end-stage renal disease. Saudi j kidney dis transpl 2015;26(4):733-738.

  9. Axelrod, D. et al. An economic assessment of contemporary kidney transplant practice. Am j transplant. 2018;18:1168–1176. Doi: 10.1111/ajt.14702.

  10. Ferguson, T. et al. Cost-effective treatment modalities for reducing morbidity associated with chronic kidney disease. Expert rev. Pharmacoecon. Outcomes res. Early online, 1–10 (2015). Doi: 10.1586/14737167.2015.1012069.

  11. Halloran, P. Immunosuppressive drugs for kidney transplantation. N engl j med 2004;351:2715-29.

  12. Guo, Z. et al. Rapamycin-inspired macrocycles with new target specificity. Nature chemistry. https:// doi.org/10.1038/s41557-018-0187-4

  13. Kajiwara, M. et al. Role of mtor inhibitors in kidney disease. Int. J. Mol. Sci. 2016, 17, 975; doi:10.3390/ ijms17060975

  14. Ma, M. et al. Mtor inhibition and kidney diseases. Transplantation 2018;102: s32–s40. Doi: 10.1097/ tp.0000000000001729.

  15. Diekmann, F. et al. Practical considerations for the use of mtor inhibitors. Transplantation research 2015, 4(suppl 1):5. Doi 10.1186/s13737-015-0029-5

  16. Weir, M. Et al. Mtor inhibition: the learning curve in kidney transplantation. European society for organ transplantation 23 (2010) 447–460. Doi:10.1111/ j.1432-2277.2010.01051.x

  17. Sanchez-escuredo, a. et al. An mtor-inhibitor- based protocol and calcineurin inhibitor (cni)- free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to cni. Esot 29 (2016) 362–368. Doi:10.1111/tri.12732.

  18. Uchida, J. et al. Introduction of everolimus in kidney transplant recipients at a late posttransplant stage. World j transplant 2018 september 10; 8(5): 150-155. Doi: 10.5500/wjt.v8.i5.150

  19. Fantus, F. et al. Roles of mtor complexes in the kidney: implications for renal disease and transplantation. Nat rev nephrol. 2016 october ; 12(10): 587– 609. Doi:10.1038/nrneph.2016.108.

  20. Kumar, J. et al. Systematic review on role of mammalian target of rapamycin inhibitors as an alternative to calcineurin inhibitors in renal transplant: challenges and window to excel. Experimental and clinical transplantation (2017) 3: 241-252. Doi: 10.6002/ ect.2016.0270

  21. Murakami, N. et al. Risk of metabolic complications in kidney transplantation after conversion to mtor inhibitor: a systematic review and meta-analysis. American journal of transplantation 2014; 14: 2317–2327. Doi: 10.1111/ajt.12852.

  22. Malvezzi, P. et al. Use of everolimus-based immunosuppression to decrease cytomegalovirus infection after kidney transplant. Experimental and clinical transplantation (2016) 4: 361-366. Doi: 10.6002/ ect.2015.0292.

  23. Jouve, T. et al. Place of mtor inhibitors in management of bkv infection after kidney transplantation. J nephropathol. 2016; 5(1): 1-7. Doi: 10.15171/ jnp.2016.01

  24. Mallat, S. et al. Cmv and bkpyv infections in renal transplant recipients receiving an mtor inhibitor–based regimen versus a cni-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin j am soc nephrol 12: ccc–ccc, 2017. Doi: https://doi.org/10.2215/cjn.13221216

  25. Au, e. Et al. Cancer in kidney transplant recipients. Nature reviews | nephrology. Https://doi. org/10.1038/ s41581-018-0022-6.

  26. Wolf S, Hoffmann Vs, Habicht A, Kauke T, Bucher J, Schoenberg M, et al. (2018) effects of mtor-is on malignancy and survival following renal transplantation: a systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. Plos one 13(4): e0194975. Https://doi. org/10.1371/journal.pone.0194975

  27. Geissler, E. K. Nat. Rev. Clin. Oncol. Advance online publication 20 october 2015; doi:10.1038/nrclinonc. 2015.186

  28. Holdaas, H. et al. Everolimus and malignancy after solid organ transplantation: a clinical update. Volume 2016, article id 4369574, 11 pages. Http://dx. doi.org/10.1155/2016/4369574

  29. Moes, D.J.A. et al. Sirolimus and everolimus in kidney transplantation, drug discov today (2015), http://dx.doi.org/10.1016/j.drudis.2015.05.006

  30. Klawitter, J. et al. Everolimus and sirolimus in transplantation-related but different. Expert opin drug saf. 2015 july ; 14(7): 1055–1070. Doi:10.1517/1 4740338.2015.1040388.

  31. Diekmann, F. et al. Mtor inhibitor–associated proteinuria in kidney transplant recipients. Transplantation reviews 26 (2012) 27–29. Doi:10.1016/j. trre.2011.10.003

  32. Paoletti, E. et al. Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. Journal of nephrology. Https://doi.org/10.1007/ s40620-019-00609-y

  33. Ponticelli, C. The pros and the cons of mtor inhibitors in kidney transplantation. Expert rev. Clin. Immunol. 10(2), 295–305 (2014). Doi: 10.1586/1744666x.2014.872562

  34. Modelli, A. Critical analysis of graft loss and death in kidney transplant recipients treated with mtor inhibitors. J bras nefrol 2017;39(1):70-78. Doi: 10.5935/0101-2800.20170012

  35. Xhaard, A. et al. A monocentric study of steroid- refractory acute graft-versus-host disease treatment with tacrolimus and mtor inhibitor. Bone marrow transplantation. Https://doi.org/10.1038/ s41409-019-0633-y.

  36. Grimbert, P. et al. Mtor inhibitors and risk for chronic antibody-mediated rejection after kidney transplantation: where are we now?. Doi: 10.1111/ tri.12975.




2020     |     www.medigraphic.com